Isaxonine

Summary

Isaxonine (CHEMBL1740513) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 137.18 Da · C7H11N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1740513
Name	Isaxonine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71169
Molecular formula	C7H11N3
Molecular weight	137.18
InChIKey	FTCYIGBVOHNHCD-UHFFFAOYSA-N

SMILES: CC(C)NC1=NC=CC=N1

IUPAC name: N-propan-2-ylpyrimidin-2-amine

Also known as: Isaxonina, Isaxonine, NSC-760406, isaxonine, ISAXONINE

Parent form; salt/anhydrous children: CHEMBL1697751

Patent coverage: 95 distinct patent families (235 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).